Halozyme Therapeutics Investor Presentation — August 2024

Document content

1Halozyme Therapeutics, Inc.

Second Quarter 2024 Financial & Operating Results

August 6, 20242Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include

forward -looking statements including, without limitation, statements concerning the

Company’s expected future growth, financial performance (including the Company’s

2024 guidance and longer term financial outlook through 2028) and expectations for

profitability, revenue (including expectations for future royalties, milestones and product

sales, and revenue durability and diversification), EBITDA, Adjusted EBITDA, non -GAAP

diluted earnings -per-share, expected growth rates of the Company’s partnered products,

potential share repurchases and the Company’s plans to potentially expand the

Company's platform through acquisitions. Forward -looking statements regarding the

Company’s ENHANZE®drug delivery technology include the possible benefits and

attributes of ENHANZE®including its potential application to aid in the dispersion and

absorption of other injected therapeutic drugs and facilitating more rapid delivery and

administration of higher volumes of injectable medications through subcutaneous delivery

and potential to decrease treatment burden, infusion related reactions and healthcare

system costs and enable new treatment sites. Forward -looking statements regarding the

Company's business may also include potential growth driven by our partners'

development and commercialization efforts (including anticipated ENHANZE®indication

and product approvals and launches and the timing related to these events), projections

for future sales revenue and market share of our collaborators’ products, potential new or

expanded ENHANZE®collaborations, collaborative targets and indications for ENHANZE®

products, the potential for co -formulation patents to extend royalty payment periods and

maintain royalty rates, and the Company’s plans to develop a high volume auto -injector

(including statements related to potential future development, approval and patient

treatment benefits of a high volume auto -injector). These forward -looking statements are

typically, but not always, identified through use of the words “expect,” "believe," "enable,"

"may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable,"

"potential," "possible," "should," "continue," and other words of similar meaning and involve

Preview truncated — download the full document for the complete content.